Tag Archives: ACAD

ACADIA Pharmaceuticals (ACAD) Receives a Buy from J.P. Morgan

J.P. Morgan analyst Cory Kasimov assigned a Buy rating to ACADIA Pharmaceuticals (ACAD – Research Report) on January 14. The company’s shares closed last Monday at $43.43. According to TipRanks.com, Kasimov is a 4-star analyst with an average return of

Cowen & Co. Remains a Buy on ACADIA Pharmaceuticals (ACAD)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $66.00. The company’s shares closed last Monday at $41.80. According to TipRanks.com, Baral is a 5-star

Monday’s Highlights at Noon: SunPower (SPWR), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), uniQure (QURE), Ballard Power Systems (BLDP)

So far Monday, January 13, NASDAQ is up 2.43% and the S&P is up 1.12%. Here are this morning’s most active stocks: SunPower (SPWR – Research Report), ACADIA Pharmaceuticals (ACAD – Research Report), Blueprint Medicines (BPMC – Research Report), uniQure

Wednesday’s Highlights at Noon: 3D Systems (DDD), Rite Aid (RAD), Karyopharm Therapeutics (KPTI), ACADIA Pharmaceuticals (ACAD), Cormedix (CRMD)

So far Wednesday, December 18, NASDAQ is up 0.07% and the S&P is down -0.1%. Here are this morning’s most active stocks: 3D Systems (DDD – Research Report), Rite Aid (RAD – Research Report), Karyopharm Therapeutics (KPTI – Research Report),

Thursday’s Midday Movers: Clovis Oncology (CLVS), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Karyopharm Therapeutics (KPTI)

So far Thursday, December 5, NASDAQ is down -1.32% and the S&P is down -0.91%. Here are this morning’s most active stocks: Clovis Oncology (CLVS – Research Report), ACADIA Pharmaceuticals (ACAD – Research Report), Amarin (AMRN – Research Report) and

ACADIA Pharmaceuticals (ACAD) Received its Third Buy in a Row

After Cowen & Co. and Needham gave ACADIA Pharmaceuticals (NASDAQ: ACAD) a Buy rating last month, the company received another Buy, this time from J.P. Morgan. Analyst Cory Kasimov maintained a Buy rating on ACADIA Pharmaceuticals yesterday. The company’s shares